Oxford Instruments sees recovery after tariff disruption

Oxford Instruments plc anticipates stable full-year performance despite a challenging first half impacted by global tariff disruption. The scientific technology provider reported first-half organic constant currency order intake up just over 1%, recovering from a Q1 decline, though revenues are expected down approximately 8% with an adjusted operating profit margin of 14.5%. The company forecasts full-year revenue, adjusted operating profit, and profit margin to be similar to the prior year on an organic constant currency basis, supported by cost-saving measures and the progressing sale of its NanoScience business, despite an additional £1 million currency headwind.

Analysis

Oxford Instruments plc navigated a challenging first half, primarily impacted by global tariff disruption, resulting in an expected 8% organic constant currency (OCC) revenue decline and a 14.5% adjusted operating profit margin. Despite a Q1 order intake decrease of 3%, the company demonstrated resilience with a significant recovery to nearly 6% growth in Q2, leading to a modest 1% H1 OCC order intake increase. This indicates an improving operational trajectory through the period.

Divisional performance was mixed, with the Imaging and Analysis segment experiencing an 11% order intake fall in Q1 before stabilizing, while the Advanced Technologies division delivered robust growth of 25% in Q1 and 26% in Q2, driven by demand in compound semiconductor markets. Proactive cost-saving measures, including workforce reductions in the Belfast imaging business, have been implemented to enhance second-half margins.

The company maintains a forecast for full-year revenue, adjusted operating profit, and profit margin to be similar to the prior year on an OCC basis, supported by anticipated H2 margin improvements and the progressing sale of its NanoScience business, expected to complete in Q3. However, an additional £1 million currency headwind, increasing the total to £5.5 million, introduces further financial pressure for the remainder of the fiscal year.

Key Decisions for Investors

• Monitor the successful completion of the NanoScience business sale in Q3, as this is a key strategic move and potential catalyst for H2 performance.
• Evaluate the effectiveness of implemented cost-saving measures on H2 margins and the overall full-year adjusted operating profit, especially in light of the increased currency headwind.
• Assess the sustained growth trajectory of the Advanced Technologies division and its exposure to compound semiconductor markets as a primary driver for future performance, offsetting potential weakness in other segments.